The Elecsys Anti-SARS-CoV-2 S antibody test would specifically target antibodies against the SARS-CoV-2 spike protein responsible for binding to the host cell receptor, which is required for the virus to enter the host cell.
The majority of current candidate vaccines aim to induce an antibody response against the spike protein.
“The new quantitative Elecsys antibody test can play a pivotal role in vaccine clinical trials as well as helping clinicians assess patients immune response,” said Thomas Schinecker, CEO.
It is the 12th test in Roche’s coronavirus portfolio and the company has filed for emergency use authorization from the FDA.
Roche price has increased around 14% YTD. While Quant Rating is Neutral, Wall Street Analysts are Very Bullish with price target of $50.07.